<rss version="2.0">
<channel>
<title>IBTimes.com RSS Feed - Lilly</title>
<description>International Business News - Lilly</description>
<link>http://www.ibtimes.com</link>
<copyright>All articles are copyrighted by IBTimes.com</copyright>

<image>
	<title>The International Business Times - Business News, Updated daily</title> 
	<width>400</width> 
	<height>100</height> 
	<link>http://www.ibtimes.com/</link> 
	<url>http://www.ibtimes.com/images/top_logo_ibt2_3.gif</url> 
</image>


  <item>
  <title>Eli Lilly says Alimta helps lung cancer patients</title>
  <description>Eli Lilly &amp; Co. said giving advanced lung cancer patients its Alimta drug after chemotherapy increased patients' survival without tumor recurrence or progression.</description>
    <link>http://www.ibtimes.com/articles/20080516/eli-lilly-says-alimta-helps-lung-cancer-patients.htm</link> 
  <pubDate>Fri, 16 May 2008 12:50:32 EDT</pubDate>
  </item>


  <item>
  <title>Eli Lilly 1Q profit doubles, but falls short of expectations</title>
  <description>Drug maker Eli Lilly and Co. said strong sales for Cymbalta and Cialis helped double its first-quarter profit, but results missed Wall Street expectations.</description>
    <link>http://www.ibtimes.com/articles/20080421/eli-lilly-1q-profit-doubles-but-falls-short-of-expectations.htm</link> 
  <pubDate>Mon, 21 Apr 2008 09:46:08 EDT</pubDate>
  </item>


  <item>
  <title>Eli Lilly 1Q profit doubles as Cialis, Cymbalta sales rise</title>
  <description>Eli Lilly says first-quarter profit doubled on strong growth in sales of depression treatment Cymbalta and impotence drug Cialis, as well as fewer charges.</description>
    <link>http://www.ibtimes.com/articles/20080421/eli-lilly-1q-profit-doubles-as-cialis-cymbalta-sales-rise.htm</link> 
  <pubDate>Mon, 21 Apr 2008 06:56:49 EDT</pubDate>
  </item>


  <item>
  <title>Earnings Preview: Eli Lilly seen posting positive 1Q results</title>
  <description>
Eli Lilly &amp; Co. reports earnings for the first quarter on Monday. The following is a summary of key developments and analyst opinion related to the period.

OVERVIEW: Legal expenses could continue na...</description>
    <link>http://www.ibtimes.com/articles/20080418/earnings-preview-eli-lilly-seen-posting-positive-1q-results.htm</link> 
  <pubDate>Fri, 18 Apr 2008 12:03:07 EDT</pubDate>
  </item>


  <item>
  <title>Eli Lilly to cut 500 jobs, streamline manufacturing</title>
  <description>
Drug developer Eli Lilly and Co. said Wednesday it is cutting up to 500 jobs and streamlining manufacturing operations in Indianapolis that deal with active ingredients for several insulin products.
...</description>
    <link>http://www.ibtimes.com/articles/20080416/eli-lilly-to-cut-500-jobs-streamline-manufacturing.htm</link> 
  <pubDate>Wed, 16 Apr 2008 11:06:15 EDT</pubDate>
  </item>


  <item>
  <title>Ahead of the Bell: Eli Lilly</title>
  <description>
A Goldman Sachs analyst expects larger profits for drug maker Eli Lilly, as its key products are selling well.

James Kelly raised his profit estimates for 2008 through 2012, saying U.S. sales are st...</description>
    <link>http://www.ibtimes.com/articles/20080407/ahead-of-the-bell-eli-lilly.htm</link> 
  <pubDate>Mon, 07 Apr 2008 08:18:39 EDT</pubDate>
  </item>


  <item>
  <title>Eli Lilly Spent $4.36M Lobbying in 2007</title>
  <description>Drugmaker Eli Lilly &amp; Co. spent $4.36 million last year lobbying the federal government on various prescription drug issues. The Indianapolis-based company lobbied on legislation affecting user fees companies pay the Food and Drug Administration to review their drugs.</description>
    <link>http://www.ibtimes.com/articles/20080331/eli-lilly-spent-4-36m-lobbying-in-2007.htm</link> 
  <pubDate>Mon, 31 Mar 2008 17:10:01 EDT</pubDate>
  </item>


  <item>
  <title>New Eli Lilly CEO Walks Into Tough Road</title>
  <description>John Lechleiter could pick any mode of transportation he wants for his commute to the executive suite at Eli Lilly and Co. Most days, he chooses his feet.</description>
    <link>http://www.ibtimes.com/articles/20080330/new-eli-lilly-ceo-walks-into-tough-road.htm</link> 
  <pubDate>Sun, 30 Mar 2008 13:36:01 EDT</pubDate>
  </item>


  <item>
  <title>A Look at Eli Lilly's Incoming CEO</title>
  <description>NAME _ John Lechleiter AGE _ 54</description>
    <link>http://www.ibtimes.com/articles/20080330/a-look-at-eli-lillys-incoming-ceo.htm</link> 
  <pubDate>Sun, 30 Mar 2008 12:56:28 EDT</pubDate>
  </item>


  <item>
  <title>Eli Lilly New CEO Walks Into Tough Road</title>
  <description>John Lechleiter could pick any mode of transportation he wants for his commute to the executive suite at Eli Lilly and Co. Most days, he chooses his feet.</description>
    <link>http://www.ibtimes.com/articles/20080330/eli-lilly-new-ceo-walks-into-tough-road.htm</link> 
  <pubDate>Sun, 30 Mar 2008 12:55:06 EDT</pubDate>
  </item>


  <item>
  <title>Lilly Draws Heat From Pension CalPERS</title>
  <description>The country's largest public pension fund plans to withhold votes for three Eli Lilly and Co. directors, including incoming CEO John Lechleiter, at next month's annual meeting.</description>
    <link>http://www.ibtimes.com/articles/20080327/lilly-draws-heat-from-pension-calpers.htm</link> 
  <pubDate>Thu, 27 Mar 2008 18:10:12 EDT</pubDate>
  </item>


  <item>
  <title>Lilly Settles Alaska Suit Over Zyprexa</title>
  <description>Eli Lilly and Co. and Alaska announced a $15 million settlement Wednesday in the state's lawsuit over the use of the drug Zyprexa in its Medicaid program.</description>
    <link>http://www.ibtimes.com/articles/20080326/lilly-settles-alaska-suit-over-zyprexa.htm</link> 
  <pubDate>Wed, 26 Mar 2008 06:32:05 EDT</pubDate>
  </item>


  <item>
  <title>Conn. Joins States Suing Over Zyprexa</title>
  <description>Connecticut is joining at least nine other states suing drug maker Eli Lilly and Co. over the antipsychotic drug Zyprexa. Attorney General Richard Blumenthal says Connecticut's lawsuit seeks to recover more than $190 million that the state's medical assistance program spent on Zyprexa over more than a decade.</description>
    <link>http://www.ibtimes.com/articles/20080311/conn-joins-states-suing-over-zyprexa.htm</link> 
  <pubDate>Tue, 11 Mar 2008 13:40:02 EDT</pubDate>
  </item>


  <item>
  <title>Eli Lilly Halts AIR Insulin Development</title>
  <description>Eli Lilly &amp; Co. confirmed Friday it is suspending development of its AIR Insulin program because of regulatory uncertainties. As a result, the Indianapolis-based drug company expects a first-quarter charge of $90 million to $120 million, or 5 cents to 7 cents per share. The company now expects 2008 net income of $3.73 to $3.90 per share, down from a prior range of $3.80 to $3.95 per share. Lilly maintained its guidance for adjusted income of $3.85 to $4 per share.</description>
    <link>http://www.ibtimes.com/articles/20080307/eli-lilly-halts-air-insulin-development.htm</link> 
  <pubDate>Fri, 07 Mar 2008 18:55:56 EST</pubDate>
  </item>


  <item>
  <title>State: No Alerts on Zyprexa Side Effects</title>
  <description>Eli Lilly and Co. failed to adequately warn doctors and patients of dangerous side effects associated with its drug Zyprexa, an attorney for Alaska said Wednesday in opening arguments in the state's lawsuit against the drug maker.</description>
    <link>http://www.ibtimes.com/articles/20080306/state-no-alerts-on-zyprexa-side-effects.htm</link> 
  <pubDate>Thu, 06 Mar 2008 02:23:20 EST</pubDate>
  </item>


  <item>
  <title>More Study Needed for Zyprexa Injection</title>
  <description>Regulators need to learn more about the excessive sedation triggered in some patients by a longer-lasting version of Eli Lilly and Co.'s top-selling drug Zyprexa before they can approve the treatment.</description>
    <link>http://www.ibtimes.com/articles/20080228/more-study-needed-for-zyprexa-injection.htm</link> 
  <pubDate>Thu, 28 Feb 2008 16:53:46 EST</pubDate>
  </item>


  <item>
  <title>Lilly Slips on Zyprexa LAI Rejection</title>
  <description>Shares of Eli Lilly &amp; Co. declined Thursday after the Food and Drug Administration rejected an injectable version of its schizophrenia drug Zyprexa. The FDA said Lilly did not provide enough information about cases in which patients who took the injection, called Zyprexa Adhera or Zyprexa long-acting injection (LAI), were excessively sedated. The agency asked for more information about the causes and risks of the excessive sedation, issuing a non-approvable letter.</description>
    <link>http://www.ibtimes.com/articles/20080228/lilly-slips-on-zyprexa-lai-rejection.htm</link> 
  <pubDate>Thu, 28 Feb 2008 11:08:32 EST</pubDate>
  </item>


  <item>
  <title>FDA Gives Eli Lilly Drug Priority Review</title>
  <description>Partners Eli Lilly and Co. and Tokyo-based Daiichi Sankyo Co. said Thursday the Food and Drug Administration gave their anti-clotting drug candidate prasugrel priority review.</description>
    <link>http://www.ibtimes.com/articles/20080221/fda-gives-eli-lilly-drug-priority-review.htm</link> 
  <pubDate>Thu, 21 Feb 2008 18:11:05 EST</pubDate>
  </item>


</channel>
</rss>